Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Wall Street Zen

Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other equities analysts also recently weighed in on TSHA. Needham & Company LLC lifted their target price on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday. The Goldman Sachs Group set a $11.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, December 4th. Wells Fargo & Company raised their price objective on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. UBS Group set a $11.00 target price on shares of Taysha Gene Therapies in a report on Thursday, December 4th. Finally, Chardan Capital restated a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $11.09.

Taysha Gene Therapies Stock Down 3.5%

Taysha Gene Therapies stock opened at $4.40 on Friday. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $6.02. The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.20. The firm has a 50 day moving average price of $4.63 and a 200-day moving average price of $4.57. The company has a market capitalization of $1.26 billion, a P/E ratio of -12.94 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. Taysha Gene Therapies had a negative return on equity of 56.64% and a negative net margin of 1,144.97%.The business had revenue of $5.49 million during the quarter, compared to analyst estimates of $1.89 million. As a group, equities analysts predict that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Buying and Selling

In other Taysha Gene Therapies news, CFO Kamran Alam sold 78,968 shares of the company’s stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $4.75, for a total value of $375,098.00. Following the completion of the sale, the chief financial officer owned 1,467,635 shares of the company’s stock, valued at $6,971,266.25. This represents a 5.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Sean P. Nolan sold 136,789 shares of the company’s stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $649,747.75. Following the completion of the sale, the chief executive officer directly owned 2,949,569 shares of the company’s stock, valued at $14,010,452.75. This trade represents a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 598,623 shares of company stock worth $2,822,188. Insiders own 3.78% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

Several institutional investors have recently bought and sold shares of TSHA. Caitong International Asset Management Co. Ltd increased its stake in Taysha Gene Therapies by 698.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 25,577 shares of the company’s stock worth $141,000 after purchasing an additional 22,373 shares during the period. Seven Fleet Capital Management LP bought a new stake in Taysha Gene Therapies during the 4th quarter valued at $920,000. Invesco Ltd. raised its holdings in Taysha Gene Therapies by 376.3% during the 4th quarter. Invesco Ltd. now owns 1,332,780 shares of the company’s stock valued at $7,330,000 after buying an additional 1,052,987 shares during the last quarter. Oracle Investment Management Inc. purchased a new stake in Taysha Gene Therapies during the 4th quarter valued at $1,458,000. Finally, Voloridge Investment Management LLC purchased a new stake in Taysha Gene Therapies during the 4th quarter valued at $301,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Taysha Gene Therapies

Here are the key news stories impacting Taysha Gene Therapies this week:

• Positive Sentiment: Q4 2025 results topped expectations — reported EPS of ~$-0.087 vs. consensus ~$-0.096 and revenue of $5.49M well above estimates; management highlighted momentum on programs and financial results. Earnings Call Transcript (InsiderMonkey)
• Positive Sentiment: TSHA‑102 pivotal trial enrollment advancing and company says it’s on track to complete dosing in Q2 2026 with a 2026 BLA submission path — a clear clinical catalyst for future value. BLA Submission Path (MSN)
• Positive Sentiment: Analyst optimism picked up — Needham raised its price target to $12 (buy) and Chardan reaffirmed a $12 buy target, signaling sizable upside from current levels and likely contributing to increased attention. Analyst Coverage (Benzinga)
• Positive Sentiment: Company highlighted a strong cash position on the earnings call, which supports ongoing pivotal enrollment and development activity. Earnings Highlights (Yahoo Finance)
• Neutral Sentiment: Full earnings/management commentary and call transcripts are available from multiple outlets for investors who want the full details and Q&A. Transcript (Seeking Alpha)
• Negative Sentiment: Company remains unprofitable with a very negative net margin and negative return on equity; development risk and cash burn remain material risks until regulatory milestones or commercialization are achieved. Full Results & Corporate Update (GlobeNewswire)

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.